Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Unlimited Watchlists, Portfolios, Screeners, and other Barchart tools. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Centessa Pharmaceuticals Plc ADR (CNTA)

Centessa Pharmaceuticals Plc ADR (CNTA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 375,469
  • Shares Outstanding, K 94,339
  • Annual Sales, $ 0 K
  • Annual Income, $ -381,900 K
  • 60-Month Beta 0.11
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.91
Trade CNTA with:

Options Overview Details

View History
  • Implied Volatility 104.69% ( +26.21%)
  • Historical Volatility 74.83%
  • IV Percentile 42%
  • IV Rank 46.17%
  • IV High 220.15% on 09/08/22
  • IV Low 5.64% on 07/15/22
  • Put/Call Vol Ratio 0.00
  • Today's Volume 0
  • Volume Avg (30-Day) 2
  • Put/Call OI Ratio 0.25
  • Today's Open Interest 115
  • Open Int (30-Day) 124

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/22
See More
  • Average Estimate -0.49
  • Number of Estimates 2
  • High Estimate -0.46
  • Low Estimate -0.52
  • Prior Year -0.45
  • Growth Rate Est. (year over year) -8.89%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.73 +3.49%
on 10/03/22
4.99 -22.65%
on 09/15/22
-0.85 (-18.05%)
since 09/02/22
3-Month
3.62 +6.73%
on 08/22/22
6.09 -36.62%
on 07/08/22
-1.12 (-22.49%)
since 07/05/22
52-Week
2.88 +33.80%
on 06/03/22
17.73 -78.23%
on 10/21/21
-12.05 (-75.74%)
since 10/05/21

Most Recent Stories

More News
CNTA ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of November 28, 2022 in the Class Action Filed on Behalf of Centessa Pharmaceuticals plc Shareholders

/PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Centessa Pharmaceuticals plc (NASDAQ:...

CNTA : 3.86 (-3.02%)
Bronstein, Gewirtz & Grossman, LLC, A Top Firm, Notifies Centessa Pharmaceuticals plc (CNTA) Investors of Class Action and Encourages Investors to Actively Participate

/PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Centessa...

CNTA : 3.86 (-3.02%)
INVESTOR NOTICE: Centessa Pharmaceuticals plc Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit – CNTA

Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Centessa Pharmaceuticals plc (NASDAQ: CNTA): (i) American Depositary Shares (“ADSs”) pursuant and/or traceable to the Offering...

CNTA : 3.86 (-3.02%)
Incyte Announces Agreement to Acquire Medicxi-backed Villaris Therapeutics and Auremolimab (VM6), an Anti-IL-15Rβ Monoclonal Antibody

Incyte (NASDAQ:INCY) today announced that the Company has entered into an agreement to acquire Villaris Therapeutics, an asset-centric biopharmaceutical company seeded by Medicxi and focused on the development...

INCY : 69.50 (-0.09%)
MOLN : 6.54 (-5.76%)
PCVX : 24.00 (+1.82%)
AURA : 13.90 (-1.63%)
CNTA : 3.86 (-3.02%)
INVESTOR ALERT: Centessa Pharmaceuticals plc Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - CNTA

SAN DIEGO, Oct. 1, 2022 PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Centessa Pharmaceuticals plc...

CNTA : 3.86 (-3.02%)
CENTESSA PHARMACEUTICALS SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Centessa Pharmaceuticals plc - CNTA

Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until November 28, 2022 to file lead plaintiff applications...

CNTA : 3.86 (-3.02%)
Centessa Pharmaceuticals plc Shareholder Update: Robbins LLP Reminds Investors of Class Action Against Centessa Pharmaceuticals plc (CNTA)

The Class : Shareholder rights law firm Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities that purchased Centessa Pharmaceuticals plc (NASDAQ:...

CNTA : 3.86 (-3.02%)
SHAREHOLDER ACTION NOTICE: The Schall Law Firm Encourages Investors in Centessa Pharmaceuticals plc with Losses of $100,000 to Contact the Firm

The Schall Law Firm , a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Centessa Pharmaceuticals plc (“Centessa” or “the Company”) (NASDAQ: ...

CNTA : 3.86 (-3.02%)
CENTESSA ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Centessa Pharmaceuticals Plc and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Centessa Pharmaceuticals Plc (“Centessa” or the “Company”)...

CNTA : 3.86 (-3.02%)
INVESTOR ALERT: Centessa Pharmaceuticals plc Investors with Substantial Losses Have Opportunity to Lead the Centessa Class Action Lawsuit - CNTA

Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Centessa Pharmaceuticals plc (NASDAQ: CNTA): (i) American Depositary Shares (“ADSs”) pursuant and/or traceable to the Offering...

CNTA : 3.86 (-3.02%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Centessa Pharmaceuticals plc is a clinical-stage company employing its innovative asset-centric business model to discover, develop and ultimately deliver impactful medicines to patients. Centessa Pharmaceuticals plc is based in Cambridge, United Kingdom.

See More

Key Turning Points

3rd Resistance Point 4.12
2nd Resistance Point 4.03
1st Resistance Point 3.94
Last Price 3.86
1st Support Level 3.76
2nd Support Level 3.67
3rd Support Level 3.58

See More

52-Week High 17.73
Fibonacci 61.8% 12.06
Fibonacci 50% 10.31
Fibonacci 38.2% 8.56
Last Price 3.86
52-Week Low 2.88

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar